Clinical study of guizhi fuling pill combined with PD-1 in the treatment of advanced ovarian cancer
Objective To study the clinical efficacy of guizhi fuling pill combined with carrellizumab(PD-1)in the treatment of advanced ovarian cancer.Methods 60 patients with advanced ovarian cancer were selected and divided into control group and experimental group according to random drawing method,with 30 cases in each group.The control group was treated with carrilizumab regimen,and the experimental group was treated with guizhi fuling pill based on the control group.The tumor indexes,objective efficacy and TCM syndrome scores of the two groups were compared before and after treatment.Results After treatment,carbohydrate antigen 125(CA125)indexes of both groups were significantly decreased,and the test group was significantly lower than the control group(P＜0.05).The objective remission rate and disease control rate of experimental group were 33.33％and 60.00％,respectively,which were significantly higher than those of control group(10.00％and 33.33％,P＜0.05).After treatment,the scores of fatigue,abdominal distension and abdominal pain in experimental group were lower than those before treatment(P＜0.05).After treatment,the scores of fatigue and abdominal pain in experimental groups were lower than those in control group(P＜0.05).Conclusion The treatment of advanced ovarian cancer patients with guizhi fuling pill combined with carrellizumab can reduce the expression level of CA125,improve the objective curative effect of patients,and significantly reduce the TCM syndrome score of patients,which is worthy of clinical promotion.
万方数据
维普
